[18F]FAraG (VisAcT) PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy
Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans
[18F]F-AraG Imaging in Bladder Cancer Patients + Atezolizumab
